Cloud Pharmaceuticals expands advisory board
Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has added members to its advisory board. The board is comprised of four leaders from industry and academia with experience in complex molecular and macromolecular systems, biophysics, translational research and drug discovery and development. The advisors collaborate with Cloud Pharmaceuticals’ board of directors to provide insight on needs and opportunities within the pharmaceutical industry.
“The pharmaceutical industry is on the cusp of major transformation. Companies that readily apply new digital technologies to the drug design and development process will most successfully navigate this transition,” said Ed Addison, Cloud Pharmaceuticals chairman and CEO. “We see one of Cloud Pharmaceuticals’ roles as being a pioneer and positive influence on the digital disruption of drug design. Our advisors validate the merits of our approach and their expertise helps guide our ongoing research and development efforts.”
Members of the advisory board include:
- David N. Beratan, Ph.D. —R.J. Reynolds Professor, Duke University
- Harold “Skip” Garner, Ph.D. —director, Medical Informatics and Systems Division, Virginia Bioinformatics Institute, Virginia Tech
- Robert A. Hromas, M.D., FACP—chairman, University of Florida department of Medicine
- Martin Ogletree, Ph.D. —Owner, Points & Assists: CV Research and Drug Development; adjunct professor of pharmacology, Vanderbilt University School of Medicine